South Korea
· Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 1.69 trillion. The enterprise value is 1.76 trillion.
| Market Cap | 1.69T |
| Enterprise Value | 1.76T |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
L&C BIO Co.,LTD has 24.62 million shares outstanding. The number of shares has increased by 14.05% in one year.
| Current Share Class | 24.62M |
| Shares Outstanding | 24.62M |
| Shares Change (YoY) | +14.05% |
| Shares Change (QoQ) | -12.18% |
| Owned by Insiders (%) | 26.25% |
| Owned by Institutions (%) | 11.99% |
| Float | 17.29M |
Valuation Ratios
The trailing PE ratio is 22.35.
| PE Ratio | 22.35 |
| Forward PE | n/a |
| PS Ratio | 21.17 |
| PB Ratio | 6.35 |
| P/TBV Ratio | 30.23 |
| P/FCF Ratio | 5,065.80 |
| P/OCF Ratio | 246.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 234.26, with an EV/FCF ratio of 5,254.55.
| EV / Earnings | 22.52 |
| EV / Sales | 21.96 |
| EV / EBITDA | 234.26 |
| EV / EBIT | n/a |
| EV / FCF | 5,254.55 |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.35.
| Current Ratio | 0.70 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 12.58 |
| Debt / FCF | 282.13 |
| Interest Coverage | 0.04 |
Financial Efficiency
Return on equity (ROE) is 37.20% and return on invested capital (ROIC) is 0.02%.
| Return on Equity (ROE) | 37.20% |
| Return on Assets (ROA) | 0.02% |
| Return on Invested Capital (ROIC) | 0.02% |
| Return on Capital Employed (ROCE) | 0.04% |
| Revenue Per Employee | 567.32M |
| Profits Per Employee | 553.19M |
| Employee Count | 141 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.81 |
Taxes
| Income Tax | -6.25B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +320.02% in the last 52 weeks. The beta is 1.08, so L&C BIO Co.,LTD's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +320.02% |
| 50-Day Moving Average | 53,984.00 |
| 200-Day Moving Average | 34,856.65 |
| Relative Strength Index (RSI) | 70.58 |
| Average Volume (20 Days) | 606,610 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 79.99 billion and earned 78.00 billion in profits. Earnings per share was 3,050.54.
| Revenue | 79.99B |
| Gross Profit | 41.36B |
| Operating Income | 117.56M |
| Pretax Income | 71.96B |
| Net Income | 78.00B |
| EBITDA | 7.50B |
| EBIT | 117.56M |
| Earnings Per Share (EPS) | 3,050.54 |
Balance Sheet
The company has 41.74 billion in cash and 94.33 billion in debt, giving a net cash position of -52.59 billion or -2,136.30 per share.
| Cash & Cash Equivalents | 41.74B |
| Total Debt | 94.33B |
| Net Cash | -52.59B |
| Net Cash Per Share | -2,136.30 |
| Equity (Book Value) | 266.71B |
| Book Value Per Share | 10,406.35 |
| Working Capital | -62.47B |
Cash Flow
In the last 12 months, operating cash flow was 6.86 billion and capital expenditures -6.52 billion, giving a free cash flow of 334.36 million.
| Operating Cash Flow | 6.86B |
| Capital Expenditures | -6.52B |
| Free Cash Flow | 334.36M |
| FCF Per Share | 13.58 |
Margins
Gross margin is 51.70%, with operating and profit margins of 0.15% and 97.51%.
| Gross Margin | 51.70% |
| Operating Margin | 0.15% |
| Pretax Margin | 89.95% |
| Profit Margin | 97.51% |
| EBITDA Margin | 9.38% |
| EBIT Margin | 0.15% |
| FCF Margin | 0.42% |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.07%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.07% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1.44% |
| Buyback Yield | -14.05% |
| Shareholder Yield | -13.97% |
| Earnings Yield | 4.61% |
| FCF Yield | 0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Oct 12, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 2.12 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.12 |
| Piotroski F-Score | 4 |